Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2011

View Archived Issues

Lipoxen provides update on pipeline and other activities

Researchers present structure and new pharmacological data on AZD-9668

Sanofi patents novel tryptase beta inhibitors

Ono Pharmaceutical reviews activities of first quarter of fiscal year 2011

Polish health authorities clear phase IIa trial of oral CD3-targeted immunotherapy in hepatitis C

Hybrigenics presents new inhibitors of ubiquitin carboxyl-terminal hydrolase 7

FDA approves second single-pill complete antiretroviral therapy for untreated HIV-1 infection

Merck & Co. prepares new HCV NS5B inhibitors

Biogen Idec and Abbott report on phase II registrational study of DAC HYP

FDA assigns PDUFA date for Affymax's peginesatide NDA

Roche synthesizes new JAK1 inhibitors

Nereus Pharmaceuticals presents novel dehydrophenylahistins for cancer

New molecules for diabetic foot ulcers prepared

Topline data reported from two phase II studies of ADL-5945

Genesis Biopharma signs agreement to develop cancer immunotherapies

Tuberculosis vaccine enters phase IIb trial in HIV-infected adults

FDA sets new PDUFA action date for Bydureon

Neoprobe submits NDA for Lymphoseek

Isis Pharmaceuticals and CHDI Foundation renew collaboration for Huntington's disease

Jennerex raises funds to support JX-594 development

Amorfix provides update on preclinical development of anticancer therapeutic antibodies

MediciNova enters collaboration for phase II trial of ibudilast in headache disorder

Yaupon raises funds to support review process of mycosis fungoides therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...